This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Tuberculosis (TB)	Mtb72F	<p>Studies in nonhuman primates suggest that the TB vaccine Mtb72F could help boost the efficacy of another TB vaccine—bacillus Calmette-Guérin (BCG). In a macaque model of TB, an initial vaccination with BCG followed by a boost with Mtb72F formulated in GlaxoSmithKline plc's adjuvant AS02A induced long-term protection against TB that was superior to that seen using vaccination with BCG alone. The Mtb72F vaccine is in Phase II trials.</p> <p>There are at least four TB vaccines in development stages ranging from preclinical to Phase II.</p> <p>SciBX 2(6); doi:10.1038/scibx.2009.233 Published online Feb. 12, 2009</p>	Patented worldwide by GSK; licensing status undisclosed	<p>Reed, S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 2, 2009; doi:10.1073/pnas.0712077106</p> <p>Contact: Steven Reed, Infectious Disease Research Institute, Seattle, Wash. e-mail: sreed@idri.org</p>